LVTX - LAVA Therapeutics NV
IEX Last Trade
0.9307
-0.069 -7.446%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:01:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.00
-0.07
-6.93%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.32%
1 Month
-39.43%
3 Months
-40.54%
6 Months
-49.73%
1 Year
-35.42%
2 Year
-71.32%
Key data
Stock price
$0.93
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.00 - $6.47
52 WEEK CHANGE
-$37.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Stephen A. Hurly
Region: US
Website: lavatherapeutics.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lavatherapeutics.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. LAVA-051 is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
Recent news